how i manage pulmonary infection in the post-transplant patient
DESCRIPTION
Pulmonary infection : Learning objectives Know the frequent causative agents of pulmonary infection after transplantation. Understand effective strategies for prophylaxis and diagnosis of pulmonary infections Know how to select antibiotic therapy to treat common causes of pulmonary infectionTRANSCRIPT
How I Manage Pulmonary Infection in the Post-Transplant Patient
Joanna Schaenman, M.D., Ph.D.David Geffen School of Medicine at UCLA
Los Angeles, CA
October 13, 2015
Pulmonary infection : Learning objectives
1.Know the frequent causative agents of pulmonary infection after transplantation.
2.Understand effective strategies for prophylaxis and diagnosis of pulmonary infections
3.Know how to select antibiotic therapy to treat common causes of pulmonary infection
Reactivation:CMV
Person-to-person:
Influenza
Environmental:Fungi
Increased risk with augmentation of immune suppression, patient comorbidities including advanced age
Pulmonary infection: the most common infection, highest mortality after solid organ transplantation
Time course of risk for pulmonary infection
Transplant
Induction
Maintenance immunosuppression
• Nosocomial infection
• Reactivation• Opportunistic
Phase 1First month
Phase 2Months 1-6
• Community-acquired
• Opportunistic
Phase 3>6 months
Kupeli, Curr Opin Pulm Medicine 2004
Prophylaxis
Common etiologies of pulmonary infection
BACTERIA• Community or
hospital acquired pneumonia
• Mycobacteria
VIRUSES• Community
acquired respiratory viruses
• CMV
FUNGI• Endemic fungi• Molds (Aspergillus)
Case 1: Fever and sepsis physiology 10 years post kidney transplant
• 47 yo woman with DM, s/p DDRT
• February developed URI symptoms, rash over thighs
• Progressive respiratory failure, fever, altered mental status, required intubation
Clinical and radiographic presentation of pneumonia is often not specific for a particular pathogen
Diagnostic approach to lung infection
Direct testing:• Sputum or tracheal aspirate for
Gram stain and bacterial, AFB, and fungal cultures
• Blood cultures• Consider bronchoscopy for
bronchoalveolar lavage• Respiratory virus testing by PCR
Indirect testing:• Consider blood or urine testing
for surrogate markers including• Coccidioides Ab• Cryptococcus ag• Histoplasma ag• Aspergillus galactomannan• Legionella urine antigen• CMV PCR
Low threshold for ordering Chest CT
Case 1: Fever and sepsis physiology 10 years post kidney transplant
• Empiric therapy: vancomycin, pipercillin/tazobactam, levaquin
• Outside hospital sputum culture positive for Streptococcus pyogenes
• Clindamycin added• Patient ultimately did
well, complete resolution of symptoms
Chest CT gives more information than CXR, but is still nonspecific for cause of infection
Yield of bronchoscopy in SOT
• Review of 47 kidney and 14 liver transplant recipients in Turkey
• 39% bronchial wash cultures were positive (47% in patients off antibiotics)
• Higher yield with transbronchial biopsy (58%)• Positive cultures included MTB, Staphylococcus
aureus, Moraxella, Klebsiella pneumoniae, E coli, Streptococcus pneumoniae, Pseudomonas, Aspergillus
Kupeli et al, Transplant Proceedings 2011; Kupeli et al., Curr Op Pulm Med 2012
Empiric treatment based on risk profile
• Community acquired pneumoniaHaemophilus influenzae, Streptococcus
pneumoniae, Mycoplasma, Legionella, viruses
• Fluoroquionolone, or ceftriaxone plus azithromycin
• Hospital acquired pneumoniaStaphylococcus aureus,
Enterobacteraciae, Acinetobacter, Pseudomonas; aspiration
• Vancomycin plus pipercillin tazobactam, levaquin
• Concern for multidrug resistant organismsESBL, CRE, MDR Pseudomonas, fungi
• Empiric broad spectrum therapy
(penem, aminoglycoside, colistin, etc)
Mycobacteria
MTB
MAC (MAI)Rapid growers (e.g. M. abscessus)
• Pre-transplant screening recommended
• Incidence of MTB 14% in developing countries, 0.5-6% in low endemic areas
• Often high mortality
Caution for drug-drug interactions with rifampin or rifabutin use
Case 2: Fever and sepsis physiology 3 mo. post kidney transplant
• 74 yo man with DM, s/p DDRT, ATG induction
• February developed URI symptoms, cough, seen in clinic but CXR showed only atelectasis
• Admitted with progressive cough, malaise
• Progressive respiratory failure, required intubation
Chest x-ray is often unrevealing in transplant recipients
Case 2: Fever and sepsis physiology 3 mo. post kidney transplant
• Empiric therapy: vancomycin, pipercillin/tazobactam, levaquin, oseltamivir
• Nasopharyngeal swab pos for RSV by respiratory viral PCR
• Ribavirin added• Progressive
respiratory failure, ARDS
Low threshold for further evaluation in vulnerable patients
• Influenza• Respiratory syncytial virus (RSV)• Human metapneumovirus• Parainfluenza • Adenovirus• Rhinovirus
Community acquired respiratory viruses (CARV)
• Diagnosis via PCR testing of nasopharyngeal swab or respiratory source
• Rx Influenza with oseltamivir or zanamivir
• Consider ribavirin for RSV, especially in lung transplant
CMV pneumonitis
• Donor positive/Recipient negative is highest risk
• Risk decreased with Valcyte prophylaxis
• Lung>heart>liver>kidney• Diagnosis via PCR testing, viral
culture, or histopathology• Treat with IV ganciclovir
Kotloff et al., 2004; Kotton, 2010
Case 3: Fever 1 year post kidney transplant
• 52 yo woman with DM, s/p DDRT
• H/o TB peritonitis• November developed
fever, chills, myalgias, fatigue, no improvement with course of levaquin
• No neurologic complaints or findings Broad diagnostic differential
for lobar pneumonia
Case 3: Fever 1 year post kidney transplant
• Empiric therapy: vancomycin, meropenem, levaquin
• Sputum culture positive for Cryptococcus gattii, Aspergillus flavus
• BAL positive for Cryptococcus and CMV; LP negative
• Started on Voriconazole
“Bad news comes in threes” (the Transplant ID motto), not “Occam’s Razor”
Clinically Important Fungi
Yeast Endemic Fungi Molds
Candida Cryptococcus CoccidioidesHistoplasmaBlastomycosis
AspergillusScedosporium, others
Agents of Mucormycosis
PCP
PCP is less common with routine TMP/SMX prophylaxis
Distribution of fungal infections by transplant type
TRANSNET Surveillance cohort
Pappas et al., CID 2010
Distribution of dimorphic endemic fungi
McP
hers
on: H
enry
's Cl
inic
al D
iagn
osis
and
Man
agem
ent b
y La
bora
tory
Met
hods
, 201
1
Histoplasmosis distribution in the Americas
Coccidioidomycosis.
• Environment is main source for exposure, but can also be donor-derived
• Reports suggest that number of infections are increasing
• Sensitivity of serologic testing is lower in immunosuppressed patients
Proia, et al. AJT 2009
Diagnosis of invasive fungal infections is challenging
• Clinical and radiographic presentation is not specific for fungal infection
• Need culture for identification and sensitivity testing• Noninvasive testing can be helpful: Aspergillus GM, antigen testing,
future PCR or breath testing
Empiric antifungal treatment
• Endemic fungi (non-severe)
• Aspergillosis
• Agents of mucormycosis
• Fluconazole, itraconaozle
• Voriconazole*
• Liposomal Amphotericin B
• Severe invasive fungal infection • Liposomal Amphotericin B, possibly combination Rx
*Watch for drug-drug interactions with tacrolimus
And last but not least…parasites
• Strongyloides: Donor derived or reactivation
Reactivation
Person-to-personEnvironmental
Think about the etiology of pulmonary infections:
BACTERIA
VIRUSES
FUNGI
To devise strategies for prevention:Vaccination, Antibiotic prophylaxis (TMP/SMX, Valcyte, azoles), Patient education
Pulmonary infection : Learning objectives
• Causative agents of pulmonary infection after transplantation include bacteria, viruses, and fungi
• Prophylaxis for PCP and CMV has decreased pneumonia incidence
• Diagnosis is important and should include sputum testing, BAL or FNA when appropriate, and noninvasive tests
• Antibiotic therapy should be based on culture-based diagnosis when possible, and on suggested clinical syndrome when unable to make clear diagnosis
References1. Fishman JA. Infections in immunocompromised hosts and organ transplant recipients: Essentials. Liver
Transpl. 2011 Oct 26;17(S3):S34–7. 2. Küpeli E, Eyüboğlu FÖ, Haberal M. Pulmonary infections in transplant recipients. Curr Opin Pulm Med.
2012 May;18(3):202–12. 3. Kupeli E, Akcay S, Ulubay G, et al. Diagnostic Utility of Flexible Bronchoscopy in Recipients of Solid Organ
Transplants. TPS. Elsevier Inc; 2011 Mar 1;43(2):543–6. 4. Kotloff RM, Ahya VN, Crawford SW. Pulmonary Complications of Solid Organ and Hematopoietic Stem
Cell Transplantation. American Journal of Respiratory and Critical Care Medicine. 2004 Jul;170(1):22–48. 5. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic
Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. CLIN INFECT DIS. 2007 Mar 1;44(Supplement 2):S27–S72.
6. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. American Journal of Respiratory and Critical Care Medicine. 2005. p. 388–416.
7. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. American Journal of Respiratory and Critical Care Medicine [Internet]. 2003 Feb 15;167(4):603–62.
8. McGrath EE, McCabe J, Anderson PB, American Thoracic Society, Infectious Diseases Society of America. Guidelines on the diagnosis and treatment of pulmonary non-tuberculous mycobacteria infection. Int. J. Clin. Pract. 2008 Dec;62(12):1947–55.
9. Ison MG. Respiratory viral infections in transplant recipients. Antivir. Ther. (Lond.). 2007;12(4 Pt B):627–38.
10. Kotton CN, Kumar D, Caliendo AM, et al., International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation. Transplantation. 2010 Apr;89(7):779–95.